Judy L. Thompson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Judy L. Thompson has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
- Steven M. Silverstein
Department of Psychiatry, University of Rochester Medical Center, Rochester, USA
4 shared publications - Aaron R. Seitz
Department of Psychology, Northeastern University, Boston, MA
2 shared publications - Anthony O. Ahmed
Department of Psychiatry, Weill Cornell Medicine, White Plains, NY, USA
2 shared publications Barbara A. Cornblatt
Department of Psychiatry Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Hempstead New York USA
2 shared publicationsBarnaby Nelson
Centre for Youth Mental Health The University of Melbourne Melbourne Victoria Australia
2 shared publications- Cassandra Wannan
The University of Melbourne
2 shared publications
Latest Publications
- Open Access
- 11 September 2026
- Published by Wiley in Acta Psychiatrica Scandinavica
Unraveling Suicidal Ideation and Behaviors in a Global Cohort of Individuals at Clinical High‐Risk for Psychosis: Multivariable Correlates and Subthreshold Psychotic Symptoms
Introduction: Suicidal ideation and behaviors (SIB) are common among individuals at clinical high risk for psychosis (CHR‐P), but their relationship with the overall clinical profile remains unclear. This study aimed to identify sociodemographic/clinical factors associated with SIB in CHR‐P individuals and to examine whether subthreshold psychotic symptom severity increases with suicidal risk. Methods: Data from the AMP SCZ initiative included 1443 CHR‐P participants aged 12–30 years. SIB were assessed using the Columbia Suicide Severity Rating Scale (C‐SSRS). Three Elastic Net regression models examined associations between suicidal ideation severity, intensity, and behaviors using 54 variables spanning sociodemographics, general psychopathology, subthreshold psychotic symptoms, and socio‐occupational functioning. Moreover, ANCOVA compared overall psychotic symptom severity across five groups defined by increasing severity on the C‐SSRS. Results: Sixty‐eight percent of participants reported lifetime suicidal ideation, and 26% reported previous suicidal behaviors. Model performance was modest but significant (cross‐validated ideation severity: R 2 = 0.161, RMSE = 0.916; ideation intensity: R 2 = 0.193, RMSE = 0.898; suicidal behavior: accuracy = 0.685; AUC = 0.675; p < 0.001). Across all models, concurrent depressive symptoms, present/past diagnosis of depression, female sex at birth, cannabis use, visual/gustatory abnormalities, guilt, and lower role functioning were the most consistent correlates of SIB. Ideation was associated with lower disorganized communication expression and lower negative symptoms, whereas behaviors were associated with schizotypal personality disorder. Other core CHR‐P symptoms, including Unusual Thoughts and Experiences, did not contribute to any model. ANCOVA ( p < 0.001, partial η 2 = 0.041) indicated increasing overall subthreshold psychotic symptoms across the SIB spectrum. Conclusion: SIB in CHR‐P individuals reflects a multidimensional clinical profile primarily outside of core psychosis‐risk symptoms. Trial Registration: ClinicalTrials.gov identifier: NCT05905003
- 11 September 2026
- Published by Wiley in Acta Psychiatrica Scandinavica
Open AccessUnraveling Suicidal Ideation and Behaviors in a Global Cohort of Individuals at Clinical High‐Risk for Psychosis: Multivariable Correlates and Subthreshold Psychotic Symptoms
Introduction: Suicidal ideation and behaviors (SIB) are common among individuals at clinical high risk for psychosis (CHR‐P), but their relationship with the overall clinical profile remains unclear. This study aimed to identify sociodemographic/clinical factors associated with SIB in CHR‐P individuals and to examine whether subthreshold psychotic symptom severity increases with suicidal risk. Methods: Data from the AMP SCZ initiative included 1443 CHR‐P participants aged 12–30 years. SIB were assessed using the Columbia Suicide Severity Rating Scale (C‐SSRS). Three Elastic Net regression models examined associations between suicidal ideation severity, intensity, and behaviors using 54 variables spanning sociodemographics, general psychopathology, subthreshold psychotic symptoms, and socio‐occupational functioning. Moreover, ANCOVA compared overall psychotic symptom severity across five groups defined by increasing severity on the C‐SSRS. Results: Sixty‐eight percent of participants reported lifetime suicidal ideation, and 26% reported previous suicidal behaviors. Model performance was modest but significant (cross‐validated ideation severity: R 2 = 0.161, RMSE = 0.916; ideation intensity: R 2 = 0.193, RMSE = 0.898; suicidal behavior: accuracy = 0.685; AUC = 0.675; p < 0.001). Across all models, concurrent depressive symptoms, present/past diagnosis of depression, female sex at birth, cannabis use, visual/gustatory abnormalities, guilt, and lower role functioning were the most consistent correlates of SIB. Ideation was associated with lower disorganized communication expression and lower negative symptoms, whereas behaviors were associated with schizotypal personality disorder. Other core CHR‐P symptoms, including Unusual Thoughts and Experiences, did not contribute to any model. ANCOVA ( p < 0.001, partial η 2 = 0.041) indicated increasing overall subthreshold psychotic symptoms across the SIB spectrum. Conclusion: SIB in CHR‐P individuals reflects a multidimensional clinical profile primarily outside of core psychosis‐risk symptoms. Trial Registration: ClinicalTrials.gov identifier: NCT05905003
- 31 October 2024
- Published by Elsevier in Schizophrenia Research
- Vol. 274, 396-405
Visual remediation of contrast processing impairments in schizophrenia: A preliminary clinical trial
- 31 October 2024
- Published by Elsevier in Schizophrenia Research
- Vol. 274, 396-405
Visual remediation of contrast processing impairments in schizophrenia: A preliminary clinical trial
- 8 September 2024
- Published by Elsevier in Schizophrenia Research
- Vol. 274, 21-23
Hallucinations and the depth-inversion illusion in schizophrenia
- 8 September 2024
- Published by Elsevier in Schizophrenia Research
- Vol. 274, 21-23
Hallucinations and the depth-inversion illusion in schizophrenia
- Open Access
- 4 April 2024
- Published by Elsevier in Vision Research
- Vol. 219, 108394
Performance on a contour integration task as a function of contour shape in schizophrenia and controls
- 4 April 2024
- Published by Elsevier in Vision Research
- Vol. 219, 108394
Open AccessPerformance on a contour integration task as a function of contour shape in schizophrenia and controls
- 22 June 2020
- Published by Springer Nature in Psychopharmacology
- Vol. 237 (9) , 2649-2659
Amphetamine-induced striatal dopamine release in schizotypal personality disorder
Rationale Previous research has suggested that schizotypal personality disorder (SPD), a condition that shares clinical and cognitive features with schizophrenia, may be associated with elevated striatal dopamine functioning; however, there are no published studies of dopamine release within subregions of the striatum in SPD. Objectives To characterize dopamine release capacity in striatal subregions and its relation to clinical and cognitive features in SPD. Methods We used positron emission tomography with [11C]raclopride and an amphetamine challenge to measure dopamine D2-receptor availability (binding potential, BPND), and its percent change post-amphetamine (∆BPND) to index amphetamine-induced dopamine release, in subregions of the striatum in 16 SPD and 16 healthy control participants. SPD participants were evaluated with measures of schizotypal symptom severity and working memory. Results There were no significant group differences in BPND or ∆BPND in any striatal subregion or whole striatum. Among SPD participants, cognitive-perceptual symptoms were associated at trend level with ∆BPND in the ventral striatum, and disorganized symptoms were significantly negatively related to ∆BPND in several striatal subregions. Conclusions In contrast to previous findings, SPD was not associated with elevated striatal dopamine release. However, in SPD, there was a moderate positive association between ventral striatal dopamine release and severity of cognitive-perceptual symptoms, and negative associations between striatal dopamine release and severity of disorganized symptoms. Future larger scale investigations that allow for the separate examination of subgroups of participants based on clinical presentation will be valuable in further elucidating striatal DA functioning in SPD.
- 22 June 2020
- Published by Springer Nature in Psychopharmacology
- Vol. 237 (9) , 2649-2659
Amphetamine-induced striatal dopamine release in schizotypal personality disorder
Rationale Previous research has suggested that schizotypal personality disorder (SPD), a condition that shares clinical and cognitive features with schizophrenia, may be associated with elevated striatal dopamine functioning; however, there are no published studies of dopamine release within subregions of the striatum in SPD. Objectives To characterize dopamine release capacity in striatal subregions and its relation to clinical and cognitive features in SPD. Methods We used positron emission tomography with [11C]raclopride and an amphetamine challenge to measure dopamine D2-receptor availability (binding potential, BPND), and its percent change post-amphetamine (∆BPND) to index amphetamine-induced dopamine release, in subregions of the striatum in 16 SPD and 16 healthy control participants. SPD participants were evaluated with measures of schizotypal symptom severity and working memory. Results There were no significant group differences in BPND or ∆BPND in any striatal subregion or whole striatum. Among SPD participants, cognitive-perceptual symptoms were associated at trend level with ∆BPND in the ventral striatum, and disorganized symptoms were significantly negatively related to ∆BPND in several striatal subregions. Conclusions In contrast to previous findings, SPD was not associated with elevated striatal dopamine release. However, in SPD, there was a moderate positive association between ventral striatal dopamine release and severity of cognitive-perceptual symptoms, and negative associations between striatal dopamine release and severity of disorganized symptoms. Future larger scale investigations that allow for the separate examination of subgroups of participants based on clinical presentation will be valuable in further elucidating striatal DA functioning in SPD.